Carl H June Selected Research

Cytokine Release Syndrome

1/2022	PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
1/2022	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
10/2020	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children.
1/2019	Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells.
12/2018	Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.
1/2018	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
1/2018	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
12/2017	Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.
11/2017	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
2/2017	Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carl H June Research Topics

Disease

153	Neoplasms (Cancer) 12/2022 - 02/2002
25	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2022 - 04/2013
25	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 11/2006
24	Leukemia 01/2022 - 06/2004
17	Cytokine Release Syndrome 01/2022 - 04/2013
14	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2022 - 08/2011
14	Ovarian Neoplasms (Ovarian Cancer) 11/2018 - 04/2003
13	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2017 - 12/2004
11	Lymphoma (Lymphomas) 01/2022 - 03/2008
11	Infections 01/2021 - 01/2002
10	HIV Infections (HIV Infection) 01/2016 - 01/2002
8	Multiple Myeloma 12/2021 - 01/2011
7	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 02/2015
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2021 - 10/2009
6	Breast Neoplasms (Breast Cancer) 12/2017 - 03/2005
5	Carcinoma (Carcinomatosis) 11/2019 - 03/2005
5	Communicable Diseases (Infectious Diseases) 01/2019 - 02/2002
4	Pancreatic Neoplasms (Pancreatic Cancer) 12/2021 - 01/2018
4	Neuroblastoma 09/2020 - 12/2012
4	Adenocarcinoma 11/2019 - 01/2016
4	Inflammation (Inflammations) 01/2019 - 10/2009
4	Melanoma (Melanoma, Malignant) 01/2017 - 05/2003
4	Testicular Neoplasms (Testicular Cancer) 01/2016 - 04/2013
4	Mesothelioma 06/2013 - 03/2005
3	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2018
3	Sepsis (Septicemia) 01/2022 - 11/2019
3	Critical Illness (Critically Ill) 10/2020 - 01/2016
3	Bites and Stings (Sting) 10/2020 - 01/2017
3	Malignant Mesothelioma 11/2019 - 04/2010
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2018 - 12/2017
3	Persistent Infection 08/2015 - 02/2007
3	Body Weight (Weight, Body) 10/2014 - 08/2011
3	Lymphopenia (Lymphocytopenia) 12/2012 - 11/2005
2	Fibrosis (Cirrhosis) 01/2022 - 01/2019
2	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2018
2	COVID-19 01/2022 - 01/2020
2	B-Cell Lymphoma (Lymphoma, B Cell) 11/2020 - 12/2017
2	Brain Neoplasms (Brain Tumor) 01/2019 - 07/2017
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2018 - 12/2017
2	Disease Progression 11/2018 - 01/2002
2	Hodgkin Disease (Hodgkin's Disease) 01/2018 - 10/2017
2	B-Cell Leukemia (Leukemia, B Cell) 12/2017 - 10/2016

Drug/Important Bio-Agent (IBA)

119	Chimeric Antigen ReceptorsIBA 12/2022 - 03/2008
40	AntigensIBA 01/2022 - 11/2002
23	CytokinesIBA 01/2022 - 01/2002
18	tisagenlecleucelIBA 01/2022 - 04/2013
15	MesothelinIBA 12/2021 - 03/2009
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2002
10	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 08/2011
8	Messenger RNA (mRNA)IBA 01/2022 - 11/2010
8	VaccinesIBA 11/2018 - 06/2007
7	AntibodiesIBA 10/2020 - 07/2013
7	RNA (Ribonucleic Acid)IBA 01/2018 - 11/2010
7	Neoplasm Antigens (Tumor Antigens)IBA 01/2018 - 01/2003
6	epidermal growth factor receptor VIIIIBA 01/2021 - 01/2013
6	Biological ProductsIBA 10/2020 - 06/2004
6	Interleukin-2 (IL2)IBA 01/2018 - 01/2005
5	Peptides (Polypeptides)IBA 01/2021 - 01/2003
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2019 - 05/2012
5	tocilizumab (atlizumab)FDA Link 01/2019 - 04/2013
5	Pharmaceutical PreparationsIBA 12/2017 - 06/2010
4	ibrutinibIBA 11/2022 - 01/2016
4	Antiviral Agents (Antivirals)IBA 01/2022 - 11/2006
4	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2022 - 04/2013
4	ChemokinesIBA 01/2022 - 06/2015
4	InterferonsIBA 01/2019 - 11/2002
4	Sirolimus (Rapamycin)FDA Link 10/2015 - 08/2008
4	EnzymesIBA 02/2013 - 11/2002
3	B-Cell Maturation AntigenIBA 01/2022 - 01/2019
3	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022 - 03/2005
3	DNA (Deoxyribonucleic Acid)IBA 11/2019 - 01/2002
3	Melphalan (Alkeran)FDA LinkGeneric 01/2019 - 09/2015
3	Interleukin-6 (Interleukin 6)IBA 01/2017 - 08/2015
3	Surface Antigens (Surface Antigen)IBA 01/2016 - 01/2014
3	Chemokine ReceptorsIBA 06/2015 - 07/2011
3	EpitopesIBA 02/2014 - 06/2012
3	Interleukin-18 (Interleukin 18)IBA 05/2011 - 09/2008
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 11/2006
2	Single-Domain AntibodiesIBA 11/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2016
2	blinatumomabIBA 11/2019 - 10/2016
2	Immune Checkpoint InhibitorsIBA 01/2019 - 12/2018
2	CTL019 chimeric antigen receptorIBA 12/2018 - 04/2013
2	Bevacizumab (Avastin)FDA Link 11/2018 - 01/2013
2	AutoantigensIBA 01/2018 - 01/2016
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2018 - 01/2016
2	Indicators and Reagents (Reagents)IBA 01/2017 - 06/2012
2	Immunoglobulin FragmentsIBA 11/2016 - 06/2012
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 06/2015 - 07/2011

Therapy/Procedure

95	Therapeutics 01/2022 - 01/2002
71	Immunotherapy 12/2022 - 02/2002
15	Drug Therapy (Chemotherapy) 10/2020 - 01/2002
9	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 01/2010
8	Stem Cell Transplantation 01/2019 - 02/2006
5	Hematopoietic Stem Cell Transplantation 01/2017 - 06/2010
4	Transplantation 12/2017 - 01/2011
3	Highly Active Antiretroviral Therapy (HAART) 01/2016 - 06/2002
3	Cell Transplantation 04/2013 - 09/2003
2	Radiotherapy 01/2018 - 07/2013
2	Injections 12/2017 - 11/2010